India's Biocon on Generic GLP-1 Push
Biocon CEO, Shreehas Tambe, discusses their push into the generic GLP-1 market, after Novo Nordisk cut prices of its blockbuster weight-loss and diabetes medications in India. He also spoke about the company's latest set of earnings on Insight with Haslinda Amin. (Source: Bloomberg)
ORIGINAL SOURCE →via Bloomberg Markets
ADVERTISEMENT
⚡ STAY AHEAD
Events like this, convergence-verified across 689 sources, land in your inbox every Sunday. Free.
GET THE SUNDAY BRIEFING →RELATED · IN
- [FINANCE] India, Peru likely to hold talks on free trade pact in June, diplomat says
- [CONFLICT] India tests new low-cost glide bomb capability
- [CONFLICT] India pide ahorrar gasolina, evitar viajes y no comprar oro en medio de la guerra en Irán
- [ENERGY] Modi Urges Indians to Conserve Fuel as Oil Shock Spreads
- [CONFLICT] In India, Heat-triggered Insurance Offers 'Some Relief'
- [CONFLICT] Başbakan duyurdu: Hindistan'dan piyasada dengeleri değiştirecek hamle!